CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments.
Early this summer, CellCentric plans to begin Phase I testing of lead candidate CCS1477 to treat late-stage prostate cancer. The company said the funding will take the small molecule up to Phase IIb testing and that it will also explore CCS1477 in the treatment of hematological cancers.
CCS1477 is a dual inhibitor of E1A binding protein p300 (EP300; p300) and CREB binding protein (CREBBP; CBP).